NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)
Phase of Trial: Phase IV
Latest Information Update: 14 May 2014
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms NG-PROMUS
- Sponsors Boston Scientific Corporation
- 22 May 2013 Results were presented at 2013 EuroPCR, according to a Boston Scientific Corporation media release.
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2012 New trial record